table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID 19 hospitalized
COVID-19 severe or critically
Immunosuppressants drugs
abatacept ACTIV-1 abatacept
adalimumab Fakharian
anti-interleukin-6
Levilimab V.Lomakin ...
sarilumab sarilumab Sanofi phase 3 outside US sarilumab Sanofi phase 3 US REMAP-CAP sarilumab
sarilumab high dose (400mg) Lescure ...
sarilumab low dose (200mg) Lescure ...
tocilizumab Sarhan REMAP-CAP ... CORIMUNO-TOCI-ICU ... Sarhan COVACTA ... NCT04377750 ... Veiga Rosas ... Rashad CORIMUNO-TOCI-1 ... Talaschian MARIPOSA Hamed
canakinumab CAN-COVID
cenicriviroc ACTIV-1 cenicriviroc
infliximab ACTIV-1 infliximab
itolizumab Kumar
janus kinase (JAK) inhibitor
baricitinib COV-BARRIER ...
ruxolitinib Cao DEVENT
TD-0903
TD-0903 10mg Singh ...
TD-0903 1mg Singh ...
TD-0903 3mg Singh ...
tacrolimus TACROVID
thalidomide Amra

6 studies excluded by filtering options 1

5357 Cavalli, 2020 0130selection pending
5398 Ana-COVID (Huet), 2020 0133selection pending
5523 Toniati, 2020 2990excludednot a RCTrisk of bias not avaialble
5526 Price, 2020 2130excludednot a RCTrisk of bias not avaialble
6020 Annane, 2020 0130selection pending
6359 Kooistra, 2020 0100selection pending

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons